SHA:600267

4 stories mentioning SHA:600267Updated 17d ago

Every FINWIRES story that references SHA:600267, newest first.

Zhejiang Hisun Pharmaceutical Wins Pre-Bids for Five Drugs Under China Procurement System

Zhejiang Hisun Pharmaceutical (SHA:600267) and subsidiary Hanhui Pharmaceutical won pre-bids for five products under China's drug procurement program, according to a Tuesday filing with the Shanghai bourse.Three of the drugs are antibiotic injections, including imipenem and cilastatin sodium, vancomycin hydrochloride, and teicoplanin.Two other products, tacrolimus for injection and epirubicin hydrochloride, are chemotherapy drugs.

SHA:600267

Asia25d ago

Zhejiang Hisun Pharmaceutical Receives US FDA Abbreviated New Drug Application Approval for Leukemia Injection

Zhejiang Hisun Pharmaceutical (SHA:600267) received an abbreviated new drug application approval from the U.S. Food and Drug Administration for its fludarabine phosphate injection, according to a Saturday filing with the Shanghai bourse.The injection is indicated for the treatment of adult B-cell chronic lymphocytic leukemia for patients unresponsive to at least one prior alkylating agent-containing therapy or whose disease has progressed during treatment.Global sales of the injection reached $23.5 million in 2025, according to market data cited in the filing.Hisun has invested 10 million yuan for research and development of the drug.

SHA:600267

Asia52d ago

Zhejiang Hisun Pharmaceutical Gets Approval for Cytomegalovirus Medication

China's drug regulator approved Zhejiang Hisun Pharmaceutical's (SHA:600267) letermovir antiviral active ingredient, according to a Tuesday filing with the Shanghai bourse.The drug is indicated for cytomegalovirus prevention and cure in adults and children weighing 6 kilograms or more.

SHA:600267

Asia91d ago

Hisun Pharmaceutical Clinches NMPA Drug Registration for Prostate Cancer Treatment

Zhejiang Hisun Pharmaceutical (SHA:600267) received a drug registration certificate from China's National Medical Products Administration for its apalutamide tablets, according to a Friday disclosure on the Shanghai bourse.The drug is used to treat prostate cancer.

SHA:600267

Track with the FINWIRES app suite

FolioX

Track SHA:600267 in your portfolio

WheelAI

Analyze SHA:600267 options with the wheel strategy

StockInsider

See market sentiment on SHA:600267